<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095264</url>
  </required_header>
  <id_info>
    <org_study_id>20030207</org_study_id>
    <nct_id>NCT00095264</nct_id>
  </id_info>
  <brief_title>A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment
      on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving an erythroid response during the 13-week test period</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving an erythroid response during the 28-week treatment period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Hb from baseline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of red blood cell (RBC) transfusions (greater than or equal to 1 unit)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in FACT-F from baseline</measure>
  </secondary_outcome>
  <enrollment>209</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin Alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria: General: - Low risk MDS (low or intermediate-1 risk as defined by
        IPSS) and FAB classification of RA, RARS, or RAEB with blasts less than or equal to 10%
        determined via a bone marrow biopsy and CBC - Adequate iron stores determined by bone
        marrow film or section staining for iron via a bone marrow biopsy - ECOG Performance status
        score of 0, 1, or 2 Laboratory: - Local laboratory screening Hgb less than or equal to
        11.0g/dL - Adequate renal function (serum creatinine concentration less than or equal to
        2.0 mg/dL) - Adequate liver function (total bilirubin less than or equal to 2 times, ALT
        less than or equal to 3 times, and AST less than or equal to 3 times the upper limit of the
        respective normal range) Ethical: - Must be 18 years of age or older - Provide written
        Institutional Review Board (IRB)-approved informed consent before any screening procedures
        are performed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.aranesp.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008 Jul;142(3):379-93. doi: 10.1111/j.1365-2141.2008.07181.x. Epub 2008 Jun 6.</citation>
    <PMID>18540943</PMID>
  </results_reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2004</study_first_submitted>
  <study_first_submitted_qc>November 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2004</study_first_posted>
  <last_update_submitted>January 14, 2010</last_update_submitted>
  <last_update_submitted_qc>January 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

